Floatz logo

Enzalutamide

Pelvic Nodal

University of California, San FranciscoSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pelvic Nodal cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
University of California, San Francisco
Phase 2CCC
Indocyanine Green
Oxford University Hospitals NHS Trust
Phase 1/2CCC
MODERNA COVID-19 VACCINE RNA
Chimei Medical Center
D
Tozinameran
Chimei Medical Center
D
OXFORD-ASTRAZENECA COVID VACCINE
Chimei Medical Center
D
Carbon Nanoparticle Suspension
The First Affiliated Hospital with Nanjing Medical University
N/ANR

Same molecule, other indications

Enzalutamide is also rated in:

Metastatic Castration Resistant Prostate CancerDormant
BBB
Indicative ·
77 / 100
View asset →
prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
castration-resistant prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →